[go: up one dir, main page]

PE20020406A1 - 7-OXO-PYRIDO [2,3-d] PYRIMIDINES 2,6-DISUSTITUTED AS INHIBITORS OF PROTEIN KINASES - Google Patents

7-OXO-PYRIDO [2,3-d] PYRIMIDINES 2,6-DISUSTITUTED AS INHIBITORS OF PROTEIN KINASES

Info

Publication number
PE20020406A1
PE20020406A1 PE2001000860A PE2001000860A PE20020406A1 PE 20020406 A1 PE20020406 A1 PE 20020406A1 PE 2001000860 A PE2001000860 A PE 2001000860A PE 2001000860 A PE2001000860 A PE 2001000860A PE 20020406 A1 PE20020406 A1 PE 20020406A1
Authority
PE
Peru
Prior art keywords
disustituted
pyrido
pyrimidines
oxo
inhibitors
Prior art date
Application number
PE2001000860A
Other languages
Spanish (es)
Inventor
Jian Jeffrey Chen
James Patrick Dunn
David Michael Goldstein
Julie Anne Lim
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20020406A1 publication Critical patent/PE20020406A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS 2,6 DISUSTITUIDAS DE FORMULA I DONDE R1 ES H, ALQUILO; R2 ES CICLOALQUILO, CICLOALQUILO HETEROSUSTITUIDO, ARALCOXI, ALCOXI, HETEROCICLICLO, ENTRE OTROS; R3 ES H, AMINO, MONOALQUILOAMINO, DIALQUILAMINO, ACILAMINO, ALQUILO, CICLOLAQUILO, -NRa-C(=O)-Rb, ENTRE OTROS DONDE Ra ES H, ALQUILO; Rb ES HETEROCICLILO, HETEROALQUILO; AR1 Y AR2 SON ARILO. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION. SON COMPUESTOS PREFERIDOS LOS COMPUESTOS DE FORMULA II DONDE AR1 ES FENILO. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE LAS PROTEINA CINASAS Y SON UTILES PARA EL TRATAMIENTO DE ARTRITIS, ENFERMEDAD DE CROHN, ALZHEIMERREFERS TO 7-OXO-PYRIDO [2,3-d] PYRIMIDINES 2,6 DISUSTITUTED OF FORMULA I WHERE R1 IS H, ALKYL; R2 IS CYCLOALKYL, HETEROSUSTITUTED CYCLOALKYL, ARALCOXI, ALCOXI, HETERO CYCLE, AMONG OTHERS; R3 IS H, AMINO, MONOALKYLAMINE, DIALKYLAMINE, ACILAMINE, ALKYL, CYCLOLAKYL, -NRa-C (= O) -Rb, AMONG OTHERS WHERE Ra IS H, ALKYL; Rb IS HETEROCYCLYL, HETEROALKYL; AR1 AND AR2 ARE ARYL. IT ALSO REFERS TO A PROCEDURE FOR PREPARATION. THE PREFERRED COMPOUNDS ARE THE COMPOUNDS OF FORMULA II WHERE AR1 IS PHENYL. THE MENTIONED COMPOUNDS ARE INHIBITORS OF PROTEIN KINASES AND ARE USEFUL FOR THE TREATMENT OF ARTHRITIS, CROHN'S DISEASE, ALZHEIMER

PE2001000860A 2000-08-31 2001-08-28 7-OXO-PYRIDO [2,3-d] PYRIMIDINES 2,6-DISUSTITUTED AS INHIBITORS OF PROTEIN KINASES PE20020406A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22958400P 2000-08-31 2000-08-31

Publications (1)

Publication Number Publication Date
PE20020406A1 true PE20020406A1 (en) 2002-05-17

Family

ID=22861859

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000860A PE20020406A1 (en) 2000-08-31 2001-08-28 7-OXO-PYRIDO [2,3-d] PYRIMIDINES 2,6-DISUSTITUTED AS INHIBITORS OF PROTEIN KINASES

Country Status (15)

Country Link
EP (1) EP1315726A1 (en)
JP (1) JP4141830B2 (en)
KR (1) KR100571339B1 (en)
CN (1) CN1275964C (en)
AR (1) AR033681A1 (en)
AU (2) AU2001293784B2 (en)
BR (1) BR0113628A (en)
CA (1) CA2420286A1 (en)
GT (1) GT200100191A (en)
MX (1) MXPA03001821A (en)
PA (1) PA8527301A1 (en)
PE (1) PE20020406A1 (en)
UY (1) UY26918A1 (en)
WO (1) WO2002018380A1 (en)
ZA (1) ZA200301079B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018379A2 (en) * 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines
US6518276B2 (en) 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)
RU2310657C2 (en) * 2002-04-03 2007-11-20 Ф.Хоффманн-Ля Рош Аг Imidazo-condensed compounds and pharmaceutical composition containing thereof
ES2291630T3 (en) * 2002-04-19 2008-03-01 Smithkline Beecham Corporation NEW COMPOUNDS.
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
UY27939A1 (en) 2002-08-21 2004-03-31 Glaxo Group Ltd COMPOUNDS
US7129351B2 (en) 2002-11-04 2006-10-31 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
CN100357293C (en) 2002-11-18 2007-12-26 霍夫曼-拉罗奇有限公司 Diazinopyrimidines
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
KR100864393B1 (en) 2003-04-10 2008-10-20 에프. 호프만-라 로슈 아게 Pyrimido compounds
EP1648493B1 (en) * 2003-07-07 2009-12-09 Van Andel Research Institute Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
RU2348632C2 (en) * 2003-11-13 2009-03-10 Ф.Хоффманн-Ля Рош Аг Hydroxyalkyl-substituted pyrido-7-pyrimidine-7ons
WO2005105097A2 (en) * 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
EP1831215A1 (en) * 2004-11-23 2007-09-12 Ranbaxy Laboratories Limited Pyrido[2,3-d]pyrimidines as anti-inflamatory agents
EP1846403A1 (en) * 2005-02-02 2007-10-24 Ranbaxy Laboratories Limited Azabicyclo derivatives as anti-inflammatory agents
US20090221600A1 (en) * 2005-09-28 2009-09-03 Ashwani Kumar Verma Pyrido-pyridimidine derivatives useful as antiinflammatory agents
CA2636981A1 (en) 2006-01-31 2007-08-09 F. Hoffmann-La Roche Ag 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
KR100661523B1 (en) * 2006-06-09 2006-12-26 주식회사 청용산기 Improved torsion correction device mounted on carton manufacturing equipment
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JP2010509265A (en) 2006-11-09 2010-03-25 エフ．ホフマン−ラ ロシュ アーゲー Substituted 6-phenyl-pyrido [2,3-D] pyrimidin-7-one derivatives as kinase inhibitors and methods of use thereof
WO2008078249A1 (en) * 2006-12-21 2008-07-03 Ranbaxy Laboratories Limited Anti-inflammatory agents
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
KR101106162B1 (en) * 2010-04-20 2012-01-20 주식회사 청용산기 Unloading guide support unit in stitching device for packing box manufacturing equipment
US8877763B2 (en) * 2012-03-22 2014-11-04 Genosco Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors
AR095464A1 (en) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc HETEROARILO COMPOUNDS AND USES OF THE SAME
NZ711376A (en) 2013-03-15 2020-01-31 Sanofi Sa Heteroaryl compounds and uses thereof
MX374558B (en) 2013-03-15 2025-03-06 Sanofi Sa HETEROARYL COMPOUNDS AND THEIR USES.
CA2958331C (en) 2014-09-12 2019-12-17 Biolab Sanus Farmaceutica Ltda. New pyridopyrimidines derivatives compounds
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN111601593B (en) 2017-10-05 2022-04-15 弗尔康医疗公司 P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD
TWI831829B (en) 2018-09-12 2024-02-11 美商建南德克公司 Phenoxy-pyridyl-pyrimidine compounds and methods of use
SI3902803T1 (en) 2018-12-27 2023-06-30 Les Laboratoires Servier Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
EP3941919A1 (en) * 2019-01-03 2022-01-26 Genentech, Inc. Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases
AU2020284018A1 (en) * 2019-05-31 2022-01-27 Les Laboratoires Servier Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
WO2022052924A1 (en) * 2020-09-11 2022-03-17 上海凌达生物医药有限公司 Preparation method for class of nitrogen-containing fused ring compounds and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU711426B2 (en) * 1994-11-14 1999-10-14 Warner-Lambert Company 6-aryl pyrido(2,3-d)pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
TR200003429T2 (en) * 1998-05-26 2001-07-23 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as cellular growth inhibitors.

Also Published As

Publication number Publication date
GT200100191A (en) 2002-05-16
BR0113628A (en) 2003-07-01
AU9378401A (en) 2002-03-13
JP2004507541A (en) 2004-03-11
AR033681A1 (en) 2004-01-07
ZA200301079B (en) 2004-05-07
KR100571339B1 (en) 2006-04-17
PA8527301A1 (en) 2002-07-30
KR20030022422A (en) 2003-03-15
AU2001293784B2 (en) 2007-08-30
CN1275964C (en) 2006-09-20
CN1451005A (en) 2003-10-22
JP4141830B2 (en) 2008-08-27
WO2002018380A1 (en) 2002-03-07
CA2420286A1 (en) 2002-03-07
MXPA03001821A (en) 2003-06-04
EP1315726A1 (en) 2003-06-04
UY26918A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
PE20020406A1 (en) 7-OXO-PYRIDO [2,3-d] PYRIMIDINES 2,6-DISUSTITUTED AS INHIBITORS OF PROTEIN KINASES
PE20120814A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
PE20070218A1 (en) AMINO-HYDANTOIN CYCLOALKYL COMPOUNDS AND USE OF THESE FOR THE MODULATION OF ß-SECRETASE
EA200501333A1 (en) 5,7-DIAMINOPYRAZOLO [4,3-d] Pyrimidines, useful in the treatment of hypertension
PE20010211A1 (en) THIAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEIN KINASES
PE20030471A1 (en) IMIDAZOPIRIDIN COMPOUND AS 5-HT4 RECEIVER MODULATORS
EA200500342A1 (en) HETEROCYCLIC SUBSTITUTED PIPERASINES FOR THE TREATMENT OF SCHIZOPHRENIA
EA200100971A1 (en) NEW COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS
AR045595A1 (en) USEFUL COMPOSITIONS AS INHIBITORS OF KINASE PROTEINS
PE20130012A1 (en) PIRAZOLE DERIVATIVES AS JAK INHIBITORS
PE20030129A1 (en) IMIDAZOTRIAZINES
EA200200716A1 (en) ARYL CONDENSED AZOPOLYCYCLIC COMPOUNDS
UY26872A1 (en) DERIVATIVES OF THE 4- PIRIDINE PHENYL
ECSP034744A (en) N-REPLACED N-REPLACED NMDA / NR2B ANTAGONISTS
EA200200337A1 (en) DERIVATIVES OF PYRAZOLO [4,3-d] PYRIMIDINE
DE60236600D1 (en) SUBSTITUTED 1H-DIHYDROPYRAZOLE, THEIR PREPARATION AND USE
BR0008056A (en) Substituted fused pyrrolocarbazoles and cyclic isoindolones
BG66085B1 (en) Phenylalanine derivatives
EA200300248A1 (en) BICYCLOPIRASOLES, ACTIVE AS KINASE INHIBITORS, METHOD OF THEIR RECEIVING AND INCLUDING THEIR PHARMACEUTICAL COMPOSITIONS
PE20051039A1 (en) [1,8] NAPHTHYRIDIN-2-ONAS AND RELATED COMPOUNDS
EA200600973A1 (en) PYRIDO [2,3-d] PYRIMIDIN-2,4-DIAMINS AS PDE 2 INHIBITORS
PE20011066A1 (en) PYRID [2,3-d] PYRIMIDIN-2,7-DIAMINES KINE INHIBITORS
EA200600605A1 (en) REJUVENATED PENTANOLS, METHOD OF THEIR PRODUCTION AND THEIR APPLICATION AS ANTI-INFLAMMATORY MEANS
EA200400475A1 (en) SUBSTITUTED DERIVATIVES OF BENZIMIDAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF MALIGNANT TUMOR
HRP20050390A2 (en) Substituted benzoxazinones and uses thereof

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed